Macchia G, Lazzari R, Colombo N, et al. - Utilizing a very large, real-world data set, researchers investigated the activity and safety of stereotactic body radiotherapy (SBRT) in patients with metastatic, persistent, and recurrent ovarian cancer (MPR-OC). The rate of complete response (CR) to SBRT and the 24-month actuarial local control (LC) rate on “per-lesion” basis were considered as endpoints. Acute and late toxicities and the 24-month actuarial late toxicity-free survival were also assessed as secondary endpoints. The rate of CB was estimated to be 96.4%. A higher likelihood of CR was noted in relation to patient age ≤ 60 years, planning target volume ≤ 18 cm³, lymph node disease, and biologically effective dose α/β10 > 70 Gy, in the multivariate analysis. A median follow-up of 22 months was performed, which revealed 24-month actuarial LC rate of 81.9%. In the multivariate analysis, a better LC rate was observed in relation to achievement of CR and total dose >25 Gy. A total of 54 (20.7%) patients suffered mild toxicity. The 24-month late toxicity-free survival rate was estimated to be 95.1%. SBRT was proved to have activity and safety in patients with MPR-OC.